Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Histone Deacetylase Inhibitors Boost Parvovirus Cancer Killing Action

By BiotechDaily International staff writers
Posted on 28 Oct 2013
Image: Computer-generated representation of parvovirus H-1 (H-1PV) (Photo courtesy of Dr. Antonio Marchini, German Cancer Research Center).
Image: Computer-generated representation of parvovirus H-1 (H-1PV) (Photo courtesy of Dr. Antonio Marchini, German Cancer Research Center).
The anticancer action of parvoviruses can be dramatically improved by co-treating cancer cells with parvovirus and histone deacetylase inhibitors (HDACIs) such as valproic acid.

The rat parvovirus H-1PV has oncolytic and tumor-suppressive properties potentially exploitable in cancer therapy. This possibility is being explored by cancer researchers, and while results have been encouraging, they have found that it is necessary to improve the cancer-killing capability of the virus.

Towards this end, investigators at the German Cancer Research Center (Heidelberg) have sought drugs or drug combinations that would improve the ability of parvoviruses to kill cancer cells. In a paper published in the September 17, 2013, online edition of the journal EMBO Molecular Medicine they described the effect of the histone deacetylase inhibitor valproic acid (VPA) on the interaction between H-1PV and human cervical carcinoma and pancreatic carcinoma cell lines.

The investigators showed that co-treatment of cultures with the parvovirus and VPA boosted the ability of the virus to kill a range of human cervical carcinoma and pancreatic carcinoma cell lines by inducing oxidative stress, DNA damage, and apoptosis. Furthermore, in rat and mouse xenograft models, H-1PV/VPA co-treatment strongly inhibited tumor growth promoting complete tumor remission in all co-treated animals. In contrast, animals treated with the same virus dose without the drug displayed no regression, not even when a 20-times higher dose of viruses was administered.

At the molecular level, the investigators found that the parvovirus nonstructural protein NS1 modulated viral transcription and cytotoxicity, both of which were enhanced by VPA treatment. NS1 was acetylated at residues K85 and K257 and addition of VPA correlated with an enhanced rate of NS1 acetylation. In contrast, amino-acid substitution of the two acetylation sites strongly impaired NS1-mediated viral gene transcription, viral replication, and cytotoxicity. VPA induced hyper-acetylation of NS1, which converted the protein into a more active polypeptide.

"The synergistic effect of a combination of parvoviruses and valproic acid enables us to deliver both the viruses and the drug at low doses, which prevents severe side effects," said senior author Dr. Antonio Marchini, a principle investigator in virology at the German Cancer Research Center. "The results are encouraging us to carry out further tests of this combination therapy. We believe it has the potential to arrest tumor growth in severe cases of cancer. We obtained impressive results in preclinical trials with parvovirus H-1 in brain tumors. However, the oncolytic effect of the viruses is weaker in other cancers. Therefore, we are searching for ways to increase the therapeutic potential of the viruses."

Related Links:

German Cancer Research Center



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The European Commission has approved the use of Avastin combined with chemotherapy as a treatment for women with recurrent ovarian cancer (Photo courtesy of Genentech).

Drug for Treatment of Platinum Resistant Recurrent Ovarian Cancer Approved for Use in Europe

For the first time in more than 15 years the European Commission (EC) has approved a new therapeutic option for the most difficult to treat form of ovarian cancer. Ovarian cancer causes more deaths... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel
Image: The DrySyn MULTI converts any standard hotplate stirrer into a high performance reaction block (Photo courtesy of Asynt).

New Reaction Vessel Heating System Is Cleaner and Safer

Biotech and other life science researchers can create a safer, cleaner, and more efficient working environment in their laboratories by switching from oil bath-based heating of reaction vessels to a new... Read more

Business

view channel

Global Computational Biology Sector Expected to Reach over USD 4 Billion by 2020

The global market for computational biology is expected to reach USD 4.285 billion by 2020 growing at a compound annual growth rate (CAGR) of 21.1%, according to new market research. Steady surge in the usage and application of computational biology for bioinformatics R&D programs designed for sequencing genomes... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.